-+ 0.00%
-+ 0.00%
-+ 0.00%

We learned from AstraZeneca that the company's innovative drug in the field of breast cancer was included in the 2025 National Medical Insurance Drug List and mainly treats advanced HR-positive breast cancer. Carpicet was approved in China in April of this year.

Zhitongcaijing·12/07/2025 06:09:00
Listen to the news
We learned from AstraZeneca that the company's innovative drug in the field of breast cancer was included in the 2025 National Medical Insurance Drug List and mainly treats advanced HR-positive breast cancer. Carpicet was approved in China in April of this year.